A single‐tube flow cytometric procedure for enhancing the diagnosis and prognostic classification of patients with myelodysplastic syndromes

Kárai, Bettina; Bedekovics, Judit; Miltényi, Zs; Gergely, Lajos; Szerafin, László; Újfalusi, Anikó; Kappelmayer, János; Hevessy, Zs.

doi:10.1111/ijlh.12700

Cited by 10 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We believe that setting up the “Ogata score” is technically easy, time‐ and cost‐efficient, making it suitable for general use in LA laboratories. Additionally, its reproducibility has already been demonstrated by different groups …”

Section: Discussionmentioning

confidence: 80%

“…Additionally, its reproducibility has already been demonstrated by different groups. 9,23,30,31 One important drawback of the "Ogata score" is that the sen- 23 Another study evaluating the combination of the "Ogata score" with the erythroid parameters recommended by IMDSFlow working group (CD36 and CD71 distribution, CD36 expression on erythroid lineage and CD117+ erythroid precursors) showed an improved diagnostic power (sensitivity of 86% and specificity of 95%). 33 Furthermore, integrating the "Ogata score," "Wells FCSS," and the erythroid parameters recommended by IMDSFlow working group, into the so-called Integrated Flow Cytometry score (iFCs), showed 80% sensitivity and 95% specificity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

Montauban

Hernandez‐Perez

Velloso

et al. 2019

Int J Lab Hematology

View full text Add to dashboard Cite

Introduction Flow cytometry (FC) is a helpful tool for the diagnosis of myelodysplastic syndrome (MDS). Different FC score systems have been developed. The “Ogata score” is a simple diagnostic score that has been validated having a sensitivity of 69% and a specificity of 92% in low‐risk MDS. We aimed to study the feasibility and the utility of the “Ogata score” for the diagnosis of MDS among Latin America (LA) Laboratories. Methods This is a case and control study conducted in LA institutions members of Grupo Latinoamericano de Mielodisplasia (GLAM). A total of 146 MDS patients and 57 control patients were included. “Ogata score” was calculated. Results The sensitivity of “Ogata score” was 75.6% (95% CI, 66.8‐81.3), specificity was 91.2% (95% CI, 79.7‐96.7), PPV was 95.6% (95% CI, 88.5‐98.3), and NPV was 65.4% (95% CI, 49.1‐71.9). In low/intermediate‐1 IPSS patients group, the sensitivity was 70.1% (95% CI, 60.2‐78.2), specificity was 91.2% (CI‐95%, 79.7‐96.7), PPV was 94.2% (95% CI, 86.4‐97.8), and NPV was 62.1% (95% CI, 53.0‐78.7). In the group of patients “without MDS specific markers” (patients without ring sideroblasts, blast excess, or chromosomal abnormalities), the sensitivity was 66.7% (CI‐95%, 55.8‐76.0), specificity was 91.2% (95% CI, 79.7‐96.7), PPV was 92.3% (95% CI, 82.2‐97.1), and NPV was 63.5% (95% CI, 51.9‐73.5). Conclusions The diagnostic power found in this study was similar to the reported by Della‐Porta et al. Also in LA, the analysis was made in modern equipment with acquisition of at least 100 000 events which permits a good reproducibility of the results.

show abstract

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

Montauban

Hernandez‐Perez

Velloso

et al. 2019

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

“…Although reduced MFI of CD71 was detected in samples collected in either Na-heparin or K 3 -EDTA at day 2, this did not influence the percentage of the erythroid precursors. Furthermore, regardless of the type of anticoagulant, the CD71 rCV, the percentage of LBs, and the MFI of CD45, CD34 on MBs and MFI of HLA-DR on monocytes did not differ significantly even on day 2, which is important because FCS systems rely on several of them ( 6 , 8 , 29 ).…”

Section: Discussionmentioning

confidence: 90%

“…Recently a number of studies focused on non-myeloid cell populations like erythroid precursors ( 6 , 7 ). Although reduced MFI of CD71 was detected in samples collected in either Na-heparin or K 3 -EDTA at day 2, this did not influence the percentage of the erythroid precursors.…”

Section: Discussionmentioning

confidence: 99%

The impact of delayed sample handling and type of anticoagulant on the interpretation of dysplastic signs detected by flow cytometry

et al. 2018

View full text Add to dashboard Cite

IntroductionA growing body of evidence supports the usefulness of dysplastic signs detected by flow cytometry in the diagnosis of myelodysplastic syndromes (MDS). Our aim was to assess the impact of pre-analytical variables (delayed sample handling, type of anticoagulant, and different clones of antibody) in the interpretation of flow cytometric results.Material and methodsBone marrow samples were labelled and analysed immediately after aspiration and on two consecutive days. The effect of anticoagulant type was evaluated in 16 bone marrow samples. Thirty-seven different immunophenotypic variables were recorded after eight-colour staining. Furthermore, 8 normal peripheral blood samples collected in K3-EDTA and Na-heparin were examined with different clones of CD11b antibodies and four parameters were recorded with both anticoagulants on two consecutive days.ResultsFourteen significant differences were detected in the initial immunophenotype of fresh samples collected in K3-EDTA and Na-heparin. Regardless of the anticoagulant type, eleven parameters remained stable despite delayed sample handling. Due to delayed sample processing, more alterations were detected in the samples collected in K3-EDTA than in the samples collected in Na-heparin. The type of CD11b clone influenced the reduction of fluorescence intensity only in samples collected in K3-EDTA, where the alterations were contrary to the changes observed in Na-heparin.ConclusionsDelayed sample processing causes considerable immunohenotypic alterations, which can lead to false interpretation of the results. If delayed sample evaluation is unavoidable, markers that remain more stable over time should be considered with more weight in the diagnosis of MDS.

show abstract

“…Karai et al extended this scale to include erythrocyte maturation cell lines by adding CD71 and mast cell percentage, achieving higher sensitivity (84%) for low-grade MDS. 17 Gupta et al have presented cytometric scale which assumes evaluation of parameters included in Ogata score extended by evaluation of CD13/CD11b, CD13/CD16 and CD11b/CD16. 18 An important element of our work was an attempt to extend the Ogata score with immunophenotypic disorders in order to increase its diagnostic value.…”

Section: Cytometric Scales In the Diagnosis Of Myelodysplastic Syndromesmentioning

confidence: 99%

The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single‐centre real‐life experience

et al. 2021

View full text Add to dashboard Cite

Introduction: This analysis attempts to determine the diagnostic and prognostic value of bone marrow (BM) evaluation by multiparameter flow cytometry in patients with myelodysplastic syndrome (MDS). Materials and methods: The study group consisted of patients who underwent diagnostic process in the years 2008-2017 due to cytopenia and finally were diagnosed with MDS (n = 71). The comparative group included patients with cytopenia diagnosed in the same period, whose definitive diagnosis was other than MDS (n = 39). Flow cytometric evaluation of BM was performed following the recommendations of the European LeukemiaNet (ELN) in all patients.Results: The median number of immunophenotypic abnormalities found on granulocytes in the MDS group was significantly higher compared to the comparative group [2 (range 0-5) vs 0 (range 0-2); P < .0001]. Similarly, the median Ogata score was significantly higher in the MDS group [2 (range 0-4) vs 1 (range 0-3); P < .0001].Since the disturbances of the CD11b/HLA-DR and CD11b/CD13 on granulocytes were significantly more common in MDS patients, the Ogata score was extended by these abnormalities, what resulted in its higher diagnostic sensitivity (82%) while preserving high specificity (87%). The positive correlation was found between risk score determined by the Revised International Prognostic Scoring System and the number of the BM immunophenotypic abnormalities (P = .017). Conclusions: Our results indicate that the diagnostic usefulness of the Ogata score may be increased by including the abnormal expression of CD11b/HLA-DR and CD11b/CD13 on granulocytes. Moreover, our findings suggest the prognostic significance of the number of BM cytometric abnormalities in MDS. 2 of 12 | MAJCHEREK Et Al. How to cite this article: Majcherek M, Kiernicka-Parulska J, Mierzwa A, et al. The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single-centre real-life experience.

show abstract

A single‐tube flow cytometric procedure for enhancing the diagnosis and prognostic classification of patients with myelodysplastic syndromes

Abstract: We evaluated and validated a single-tube flow cytometric procedure for a simple six-parameter FCSS which has not only high diagnostic but also prognostic power.

Cited by 10 publications

References 34 publications

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

The impact of delayed sample handling and type of anticoagulant on the interpretation of dysplastic signs detected by flow cytometry

The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single‐centre real‐life experience

Contact Info

Product

Resources

About